Literature DB >> 1959991

Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.

J J Oudejans1, R J Slebos, F A Zoetmulder, W J Mooi, S Rodenhuis.   

Abstract

To study the possible role of ras oncogene activation in the dissemination of colon cancer, we determined point mutations in codons 12, 13 and 61 in K- and N-ras in 3 groups of tumors: (A) primary tumors of patients who had undergone surgery for Dukes' B (early-stage) colon cancer, (B) primary tumors and metastases from patients undergoing resection of isolated lung metastases and (C) primary tumors and metastases from patients undergoing resection of isolated liver metastases. In 129 samples from 93 patients, 54 (42%) were positive for point mutations in either K- or N-ras. Most mutations (89%) were found in the K-ras gene. In group A (n = 50) ras point mutations were detected in 16 cases (32%) (15 in K-ras and 1 in N-ras). Thirteen out of 23 cases in group B (57%) were positive for a ras point mutation: 10 in K-ras and 3 in N-ras. In group C (n = 20), point mutations in codon 12 of K-ras, but none in H- or N-ras, were found in 10 cases (50%). In 31 cases the primary tumors from the metastases in groups B and C were available for analysis and 15 contained a ras point mutation (48%). Not all mutations were present in both the primary tumor and the metastasis. In 3 instances, a mutation was detected in the metastasis but not in the primary tumor, whereas in 1 case a mutation was found in the primary tumor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959991     DOI: 10.1002/ijc.2910490613

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

Review 2.  Causes of genome instability: the effect of low dose chemical exposures in modern society.

Authors:  Sabine A S Langie; Gudrun Koppen; Daniel Desaulniers; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Amaya Azqueta; William H Bisson; Dustin G Brown; Gunnar Brunborg; Amelia K Charles; Tao Chen; Annamaria Colacci; Firouz Darroudi; Stefano Forte; Laetitia Gonzalez; Roslida A Hamid; Lisbeth E Knudsen; Luc Leyns; Adela Lopez de Cerain Salsamendi; Lorenzo Memeo; Chiara Mondello; Carmel Mothersill; Ann-Karin Olsen; Sofia Pavanello; Jayadev Raju; Emilio Rojas; Rabindra Roy; Elizabeth P Ryan; Patricia Ostrosky-Wegman; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Frederik J Van Schooten; Mahara Valverde; Jordan Woodrick; Luoping Zhang; Nik van Larebeke; Micheline Kirsch-Volders; Andrew R Collins
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 3.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Authors:  Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

4.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

5.  K-ras mutations in patients with early colorectal cancers.

Authors:  H J Andreyev; J V Tilsed; D Cunningham; S A Sampson; A R Norman; H J Schneider; P A Clarke
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

Review 6.  Behavioral genetics of the depression/cancer correlation: a look at the Ras oncogene family and the 'cerebral diabetes paradigm'.

Authors:  Janet K Brewer
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

7.  KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.

Authors:  Paloma Cejas; Miriam López-Gómez; Cristina Aguayo; Rosario Madero; Javier de Castro Carpeño; Cristóbal Belda-Iniesta; Jorge Barriuso; Víctor Moreno García; Javier Larrauri; Rocío López; Enrique Casado; Manuel Gonzalez-Barón; Jaime Feliu
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

8.  Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy.

Authors:  S Gattenlöhner; B Etschmann; V Kunzmann; A Thalheimer; M Hack; G Kleber; H Einsele; C Germer; H-K Müller-Hermelink
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375

9.  KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies.

Authors:  D Soulières; W Greer; Anthony M Magliocco; D Huntsman; S Young; M-S Tsao; S Kamel-Reid
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

10.  Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Authors:  Andreas Andreou; Scott Kopetz; Dipen M Maru; Su S Chen; Giuseppe Zimmitti; Antoine Brouquet; Junichi Shindoh; Steven A Curley; Christopher Garrett; Michael J Overman; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.